Case series of allergic bronchopulmonary aspergillosis treated successfully and safely with long-term mepolizumab

Allergol Int. 2019 Jul;68(3):377-379. doi: 10.1016/j.alit.2018.12.008. Epub 2019 Jan 28.

Authors

Seiko Soeda¹, Masako To², Yuta Kono¹, Satoshi Yamawaki¹, Ryuta Tsuzuki¹, Otohiro Katsube¹, Naoto Watanabe¹, Yasuo To³

Affiliations

¹ Department of Allergy and Respiratory Medicine, The Fraternity Memorial Hospital, Tokyo, Japan.
² Department of Allergy and Respiratory Medicine, The Fraternity Memorial Hospital, Tokyo, Japan; Department of Laboratory Medicine, Dokkyo Medical University, Saitama Medical Center, Saitama, Japan.
³ Department of Allergy and Respiratory Medicine, The Fraternity Memorial Hospital, Tokyo, Japan. Electronic address: ytou-alg@umin.ac.jp.

PMID: 30704844
DOI: 10.1016/j.alit.2018.12.008

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Allergens / immunology
Anti-Allergic Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Antigens, Fungal / immunology
Aspergillosis, Allergic Bronchopulmonary / drug therapy*
Aspergillus fumigatus / physiology*
Eosine Yellowish-(YS) / analogs & derivatives
Female
Humans
Immunoglobulin E / metabolism
Middle Aged
Thapsigargin / analogs & derivatives
Time Factors

Substances

Allergens
Anti-Allergic Agents
Antibodies, Monoclonal, Humanized
Antigens, Fungal
eosinthapsigargin
Immunoglobulin E
Thapsigargin
mepolizumab
Eosine Yellowish-(YS)